Food, drug, insect sting allergy, and anaphylaxisTime trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012
Section snippets
Hospital anaphylaxis admissions data
Australian National Hospital Morbidity Database principle diagnosis data cubes were obtained from the Australian Institute of Health and Welfare (AIHW).12 These record primary (and important secondary) discharge hospital diagnoses based on ICD-10 codes13 for each financial year (July to June; eg, 1998-1999 denotes the period July 1998 to June 1999). Previous Australian studies of hospital anaphylaxis admission rates combined data derived from ICD-9 codes (between 1993-1994 and 1997-1998) and
Hospital admissions data for allergic conditions from 1998-1999 to 2011-2012
The number of admissions to Australian hospitals recorded for anaphylaxis, asthma, and urticaria/angioedema between July 1998 and June 2012 are summarized in Table I. Over that period, total population hospital anaphylaxis admission rates per 105 population increased from 6.3 in 1998-1999 to 10.6 in 2004-2005 (a 1.7-fold increase over 7 financial years), with a further 1.5-fold increase from 12.2 in 2005-2006 to 17.7 in 2011-2012 over the next 7 financial years (Table II). In the more recent
Discussion
Consistent with other studies in Australia,1, 10, 11 the UK,2 and the United States,4 we confirmed a 1.7-fold increase in overall anaphylaxis admissions in Australia in the 7 years between 1998-1999 and 2004-2005 by reanalyzing data using ICD-10 codes alone for consistency. Importantly, we now report a further 1.5-fold increase in overall anaphylaxis admission rates and a 1.5-fold increase in FA-related anaphylaxis admissions in the subsequent 7 years between 2005-2006 and 2011-2012, which is
References (39)
- et al.
Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990-2006
Ann Allergy Asthma Immunol
(2008) - et al.
Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005
J Allergy Clin Immunol
(2007) - et al.
Anaphylaxis fatalities and admissions in Australia
J Allergy Clin Immunol
(2009) - et al.
Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012
J Allergy Clin Immunol
(2015) - et al.
Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: an analysis of the Italian Ministry of Health database
J Allergy Clin Immunol
(2015) - et al.
Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007
J Allergy Clin Immunol
(2009) - et al.
Case fatality and population mortality associated with anaphylaxis in the United States
J Allergy Clin Immunol
(2014) - et al.
The epidemiology of IgE-mediated food allergy and anaphylaxis
Immunol Allergy Clin North Am
(2012) - et al.
Are vitamins A and D important in the development of food allergy and how are they best measured?
Clin Biochem
(2014) - et al.
Peanut oral immunotherapy is not ready for clinical use
J Allergy Clin Immunol
(2010)
Paediatric food allergy trends in a community-based specialist allergy practice, 1995-2006
Med J Aust
Time trends in allergic disorders in the UK
Thorax
Trends in hospitalizations for food-induced anaphylaxis in US children, 2000-2009
J Allergy Clin Immunol
Temporal trends and racial/ethnic disparity in self-reported pediatric food allergy in the United States
Ann Allergy Asthma Immunol
Trends in allergic conditions among children: United States, 1997-2011
NCHS Data Brief
Incidence, prevalence, and trends of general practitioner-recorded diagnosis of peanut allergy in England, 2001 to 2005
J Allergy Clin Immunol
Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK
Allergy
Cited by (0)
Disclosure of potential conflict of interest: M. L. K. Tang is a board member for the Nestlé Nutrition Institute and Danone Nutricia, has received consultancy fees from Deerfield and GLG Group, has received lecture fees from Danone Nutricia, has a patent for a novel treatment for food allergy (pending in the United States, awarded in the European Union, and granted in Australia and New Zealand), and has received travel support from WISC 2014. The rest of the authors declare that they have no relevant conflicts of interest.